Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOPE: Olaparib, Palbociclib and Fulvestrant in BRCA-mutated, HR+/HER2- Metastatic Breast Cancer
NCT03685331Phase 1Completed
- Sponsor
- Abramson Cancer Center
- Start
- Oct 2020
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of olaparib, palbociclib and fulvestrant in breast cancer (4 arms), sponsored by Abramson Cancer Center. Primary endpoint: Progression-Free Survival at 7 months. Started Oct 2020; status: completed.
02
Drugs
olaparibpalbociclibfulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03685331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03685331.